Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for NVO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for NVO and 80,000+ other tickers.
See exactly how NVO's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NVO and 80,000+ other tickers.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging…
Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.
Carnegie Investment Counsel lowered its position in Novo Nordisk A/S (NYSE: NVO) by 28.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,560 shares of the company's stock after selling 48,696 shares during the quarter. Carnegie Investment Counsel's holdings
Novo remains a leader in the diabetes and weight loss drug markets. The company could make significant clinical and regulatory progress over the next few years.
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.